Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Krieg

Showing results (11-20 of 327) with videos related to

Pageof 33
Sort By:
The Journal of Investigative Dermatology|January 16, 2014
Clinician scientists and PhDs: the need to connect basic research to translational medicine-a personal experienceCarien M Niessen, Thomas Krieg
Journal of the American Academy of Dermatology|October 19, 2010
Imatinib treatment of generalized localized scleroderma (morphea)Pia Moinzadeh, Thomas Krieg, Nicolas Hunzelmann
Fibrogenesis & Tissue Repair|March 13, 2010
Cell-matrix interactions in dermal repair and scarringBeate Eckes, Roswitha Nischt, Thomas Krieg
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|May 12, 2006
[Assymetric pigmental lesions on the underarm and quickly growing nodes on the back of the hand]Gernot Herrmann, Wolfgang Groth, Thomas Krieg
Arthritis Research & Therapy|September 15, 2007
Fibrosis in connective tissue disease: the role of the myofibroblast and fibroblast-epithelial cell interactionsThomas Krieg, David Abraham, Robert Lafyatis
Annals of the Rheumatic Diseases|June 2, 2026
Reply to Chen and YehAnn-Helen S Rosendahl, Thomas Krieg
The Journal of Dermatology|January 5, 2005
Genetically modified mice as a tool to study inflammatory skin diseasesIngo Haase, Manolis Pasparakis, Thomas Krieg
The Journal of Investigative Dermatology|April 17, 2007
Keratinocyte-fibroblast interactions in wound healingSabine Werner, Thomas Krieg, Hans Smola
Journal of the American Academy of Dermatology|August 16, 2011
Combination therapy with an endothelin-1 receptor antagonist (bosentan) and a phosphodiesterase V inhibitor (sildenafil) for the management of severe digital ulcerations in systemic sclerosisPia Moinzadeh, Nicolas Hunzelmann, Thomas Krieg
Journal of Experimental Pharmacology|May 18, 2016
Pharmacology and rationale for imatinib in the treatment of sclerodermaPia Moinzadeh, Nicolas Hunzelmann, Thomas Krieg
Pageof 33

Showing results (11-20 of 327) with videos related to

Sort By:
Pageof 33
The Journal of Investigative Dermatology|January 16, 2014
Clinician scientists and PhDs: the need to connect basic research to translational medicine-a personal experienceCarien M Niessen, Thomas Krieg
Journal of the American Academy of Dermatology|October 19, 2010
Imatinib treatment of generalized localized scleroderma (morphea)Pia Moinzadeh, Thomas Krieg, Nicolas Hunzelmann
Fibrogenesis & Tissue Repair|March 13, 2010
Cell-matrix interactions in dermal repair and scarringBeate Eckes, Roswitha Nischt, Thomas Krieg
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|May 12, 2006
[Assymetric pigmental lesions on the underarm and quickly growing nodes on the back of the hand]Gernot Herrmann, Wolfgang Groth, Thomas Krieg
Arthritis Research & Therapy|September 15, 2007
Fibrosis in connective tissue disease: the role of the myofibroblast and fibroblast-epithelial cell interactionsThomas Krieg, David Abraham, Robert Lafyatis
Annals of the Rheumatic Diseases|June 2, 2026
Reply to Chen and YehAnn-Helen S Rosendahl, Thomas Krieg
The Journal of Dermatology|January 5, 2005
Genetically modified mice as a tool to study inflammatory skin diseasesIngo Haase, Manolis Pasparakis, Thomas Krieg
The Journal of Investigative Dermatology|April 17, 2007
Keratinocyte-fibroblast interactions in wound healingSabine Werner, Thomas Krieg, Hans Smola
Journal of the American Academy of Dermatology|August 16, 2011
Combination therapy with an endothelin-1 receptor antagonist (bosentan) and a phosphodiesterase V inhibitor (sildenafil) for the management of severe digital ulcerations in systemic sclerosisPia Moinzadeh, Nicolas Hunzelmann, Thomas Krieg
Journal of Experimental Pharmacology|May 18, 2016
Pharmacology and rationale for imatinib in the treatment of sclerodermaPia Moinzadeh, Nicolas Hunzelmann, Thomas Krieg
Pageof 33